journal article·2026-04Open access

In Situ Lipoprotein‐seeking Dye for in Vivo Real‐Time Imaging of Lipid Dysregulation Diseases

Yijing Du, Zetao Dang, Baofeng Xu, Jiajun Xu, Dan Wang, Yuewei Zhang, Shoujun Zhu

Advanced Science· Volume 13· Issue 19

Abstract

ABSTRACT Lipoproteins, critical transporters of cholesterol and triglycerides, are essential to cardiovascular health and pathology. However, imaging probes that can specifically target endogenous lipoproteins in situ are lacking. This study introduces an innovative lipoprotein‐seeking near‐infrared‐II (NIR‐II) dye for in vivo imaging of lipid dysregulation diseases independent of immune interactions. This dye demonstrates high affinity and specificity for lipoproteins, enabling in situ selective lipoprotein‐seeking within the body, unaffected by other proteins. The lipoprotein‐seeking dynamics can be precisely modulated through rationally tuning hydrophilic moieties of dye structure. The lipoprotein‐seeking dye enables the real‐time high‐contrast detecting subtle biological changes associated with lipid metabolism disorders, successfully delineating the presence of fatty deposits in hepatic tissues and identifying the early formation of atherosclerotic plaques in cardiovascular systems. Notably, our dye can selectively image low density lipoprotein (LDL) without highlighting high density lipoprotein (HDL) through appropriate irradiation. The NIR‐II dye's ability to target lipoproteins and provide clear imaging could revolutionize the management of lipoprotein‐related conditions, facilitating earlier interventions and more personalized treatment strategies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cerebrovascular and Carotid Artery Diseases · Nanoplatforms for cancer theranostics · Supramolecular Self-Assembly in Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Joint Laboratory of Opto‐Functional Theranostics in Medicine and Chemistry First Hospital of Jilin University Changchun P.R. China

State Key Laboratory of Supramolecular Structure and Materials Center For Supramolecular Chemical Biology College of Chemistry Jilin University Changchun P.R. China

Changbaishan Laboratory Jilin University Changchun P.R. China

Stroke Center Department of Neurology First Hospital of Jilin University Changchun P.R. China

Key Laboratory of Chemical Biology of Hebei Province College of Chemistry and Materials Science Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education Hebei University Baoding P.R. China

Funding

National Natural Science Foundation of China

References (59)

Show source-provided references
1. 10.1016/j.addr.2020.07.01910.1016/j.addr.2020.07.019 ↗
2. 10.1016/j.molmet.2021.10123810.1016/j.molmet.2021.101238 ↗
3. 10.1038/s41581‐023‐00741‐w10.1038/s41581‐023‐00741‐w ↗
4. 10.1016/j.cell.2022.04.00410.1016/j.cell.2022.04.004 ↗
5. 10.1007/s00261‐016‐1002‐610.1007/s00261‐016‐1002‐6 ↗
6. 10.3390/ijms1605974910.3390/ijms16059749 ↗
7. 10.1016/j.jacl.2023.11.00810.1016/j.jacl.2023.11.008 ↗
8. 10.1038/s41574‐021‐00584‐010.1038/s41574‐021‐00584‐0 ↗
9. 10.1148/radiol.202120428810.1148/radiol.2021204288 ↗
10. 10.1038/s41566‐024‐01391‐510.1038/s41566‐024‐01391‐5 ↗
11. 10.1002/adma.20190032110.1002/adma.201900321 ↗
12. 10.1038/s41551‐024‐01275‐710.1038/s41551‐024‐01275‐7 ↗
13. 10.1126/sciadv.adh782810.1126/sciadv.adh7828 ↗
14. 10.1126/sciadv.adh103710.1126/sciadv.adh1037 ↗
15. 10.1038/s41551‐019‐0494‐010.1038/s41551‐019‐0494‐0 ↗
16. 10.1038/s41565‐023‐01422‐210.1038/s41565‐023‐01422‐2 ↗
17. 10.1038/s41557‐020‐00554‐510.1038/s41557‐020‐00554‐5 ↗
18. 10.1038/s41592‐022‐01394‐610.1038/s41592‐022‐01394‐6 ↗
19. 10.1038/s41551‐023‐01003‐710.1038/s41551‐023‐01003‐7 ↗
20. 10.1038/s43586‐024‐00301‐x10.1038/s43586‐024‐00301‐x ↗
21. 10.1002/anie.20231880010.1002/anie.202318800 ↗
22. 10.1002/agt2.7004010.1002/agt2.70040 ↗
23. 10.1002/adma.20230043910.1002/adma.202300439 ↗
24. 10.1016/j.biomaterials.2020.11996310.1016/j.biomaterials.2020.119963 ↗
25. 10.1016/j.jconrel.2008.03.01910.1016/j.jconrel.2008.03.019 ↗
26. Tumor‐Activatable Nanoparticles Target Low‐Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy
27. 10.1038/ncomms1567810.1038/ncomms15678 ↗
28. 10.1039/D2BM01271E10.1039/D2BM01271E ↗
29. 10.1021/bc900404y10.1021/bc900404y ↗
30. 10.1007/s00280‐018‐3626‐410.1007/s00280‐018‐3626‐4 ↗
31. 10.1016/S0169‐409X(01)00109‐010.1016/S0169‐409X(01)00109‐0 ↗
32. 10.1016/j.bbalip.2021.15902510.1016/j.bbalip.2021.159025 ↗
33. 10.1016/j.addr.2020.08.00310.1016/j.addr.2020.08.003 ↗
34. 10.1148/radiol.1009247310.1148/radiol.10092473 ↗
35. 10.1021/bc300561e10.1021/bc300561e ↗
36. 10.1021/ja069336k10.1021/ja069336k ↗
37. 10.1021/ar200017e10.1021/ar200017e ↗
38. 10.1021/acsptsci.4c0066710.1021/acsptsci.4c00667 ↗
39. 10.1016/j.ijpharm.2021.12107610.1016/j.ijpharm.2021.121076 ↗
40. 10.1016/j.ijpharm.2020.11928210.1016/j.ijpharm.2020.119282 ↗
41. 10.1016/j.jconrel.2008.05.01010.1016/j.jconrel.2008.05.010 ↗
42. 10.1126/sciadv.aaw067210.1126/sciadv.aaw0672 ↗
43. 10.1016/j.ejpb.2015.03.01910.1016/j.ejpb.2015.03.019 ↗
44. 10.1038/s41467‐020‐15323‐810.1038/s41467‐020‐15323‐8 ↗
45. 10.1002/adma.20231151510.1002/adma.202311515 ↗
46. 10.1016/j.snb.2024.13591010.1016/j.snb.2024.135910 ↗
47. 10.1038/s41467‐024‐47063‐410.1038/s41467‐024‐47063‐4 ↗
48. 10.1002/adma.20230677310.1002/adma.202306773 ↗
49. 10.1039/C5SC02396C10.1039/C5SC02396C ↗
50. 10.3390/metabo1401001210.3390/metabo14010012 ↗
51. 10.1097/MOL.000000000000093310.1097/MOL.0000000000000933 ↗
52. 10.1146/annurev.bi.38.070169.00055310.1146/annurev.bi.38.070169.000553 ↗
53. 10.1038/s41572-019-0106-z10.1038/s41572-019-0106-z ↗
54. 10.1042/cs097061510.1042/cs0970615 ↗
55. 10.1093/cvr/cvx22610.1093/cvr/cvx226 ↗
56. 10.1006/jcph.1995.103910.1006/jcph.1995.1039 ↗
57. 10.1016/0021‐9991(83)90014‐110.1016/0021‐9991(83)90014‐1 ↗
58. 10.1887/085274392010.1887/0852743920 ↗
59. 10.1016/j.nantod.2022.10144710.1016/j.nantod.2022.101447 ↗